Evaluation Of Renin Angiotensin Aldosteron System With Plasma Renin Activity In Polycystic Ovarian Syndrome

Year 2019, Volume: 16 Issue: 2, 60 - 63, 01.04.2019

Özlem Banu Tulmaç , Üçler Kısa

Abstract

Aim: The present study intends to investigate the relationship between polycystic ovarian syndrome PCOS and renin anjiotensin aldosteron system RAS .Material and Methods: It is a prospective cross-sectional study conducted at Gynecology Clinic of Faculty of Medicine in Kirikkale University. The study group consists of a total of 126 patients, aged between 18 and 40. 96 were diagnosed with PCOS, and 30 were non-PCOS patients control group . All the patients were given a fasting blood test in the morning, and the plasma renin activity PRA was assessed. Statistical analyses were performed to see the difference between the groups.Conclusion: PRA was 287 10-693 pg/ml and 213 50-802 pg/ml in PCOS and non-PCOS group, respectively. Statistically significant difference was identified between the groups p:0.048 . In brief, PRA levels increase significantly in PCOS, which indicates an activity in the RAS in PCOS.

Keywords

Plasma renin activity, polycystic ovarian syndrome, renin angiotensin aldosterone system

Polikistik Over Sendromunda Renin Anjiotensin Aldosteron Sisteminin Plazma Renin Aktivitesi ile Değerlendirilmesi

Abstract

Amaç: Polikistik over sendromu PKOS ile renin anjiotensin aldosteron RAS sisteminin ilişkisini araştırmaktır.Gereç ve Yöntemler: Çalışma Kırıkkale Üniversitesi Tıp Fakültesi Jinekoloji polikliniğine başvuran, 18-40 yaş arası, 96 PKOS tanısı alan hasta ile, 30 PKOS olmayan sağlıklı kontrol hastası toplam 126 hastanın dahil edildiği, prospektif kesitsel bir çalışmadır. Tüm hastalara sabah aç ve ayakta alınan kan örneklerinde plazma renin aktivitesi PRA çalışıldı. Gruplar arasında PRA açısından istatistiksel anlamlı bir farkın olup olmadığı değerlendirildi.Sonuç: PKOS tanısı alan hasta grubunda PRA 287 10-693 pg/ml, kontrol grubunda PRA 213 50-802 pg/ml tespit edildi. Sonuçta PKOS da PRA düzeylerinde anlamlı bir artış saptanmaktadır p=0,048 Bu artış PKOS da RAS sisteminde bir aktivasyona işaret etmektedir.

Keywords

Polikistik over sendromu, plazma renin aktivitesi, renin anjiotensin aldosteron sistemi

References

• ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome. Obstetrics and gynecology. 2018;131(6):e157-e71.
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: me- chanism and implications for pathogenesis. Endocrine reviews. 1997;18(6):774-800.
• Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. The Journal of clinical endocrinology and metabolism. 2006;91(1):48-53.
• Manrique C, Lastra G, Gardner M, Sowers JR. The Renin Angiotensin Aldosterone System in Hypertension: Roles of Insulin Resistance and Oxidative Stress. Medical Clinics of North America. 2009;93(3):569-82.
• Palumbo A, Jones C, Lightman A, Carcangiu ML, DeCherney AH, Naftolin F. Immunohistochemical localization of renin and angiotensin II in human ovaries. American journal of obstetrics and gynecology. 1989;160(1):8- 14.
• Allen AM, Moeller I, Jenkins TA, Zhuo J, Aldred GP, Chai SY, et al. An- giotensin receptors in the nervous system. Brain research bulletin. 1998;47(1):17-28.
• Kalenga MK, de Gasparo M, Thomas K, de Hertogh R. Angiotensin II and its different receptor subtypes in placenta and fetal membranes. Placenta. 1996;17(2-3):103-10.
• Leung PS. The physiology of a local renin-angiotensin system in the pancreas. The Journal of physiology. 2007;580(Pt 1):31-7.
• Palumbo A, Ávila J, Naftolin F. The Ovarian Renin–Angiotensin System (OVRAS). Reproductive Sciences. 2016;23(12):1644-55.
• Palumbo A, Pourmotabbed G, Carcangiu ML, Andrade-Gordon P, Roa L, DeCherney A, et al. Immunohistochemical localization of renin and angi- otensin in the ovary: comparison between normal women and patients with histologically proven polycystic ovarian disease. Fertility and sterility. 1993;60(2):280-4.
• Palumbo A, Carcangiu ML, Roa L, Pepperell J, Pourmotabbed G, Naftolin F. The ovarian renin-angiotensin system in polycystic ovarian syndrome. Annals of the New York Academy of Sciences. 1993;687:39-45.
• Uncu G, Sözer MC, Develioğlu O, Cengiz C. The role of plasma renin activity in distinguishing patients with polycystic ovary syndrome (PCOS) from oligomenorrheic patients without PCOS. Gynecological Endocrino- logy. 2009;16(6):447-52.
• Armanini D, Bordin L, Donà G, Sabbadin C, Bakdounes L, Ragazzi E, et al. Polycystic ovary syndrome: Implications of measurement of plasma aldosterone, renin activity and progesterone. Steroids. 2012;77(6):655-8.
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human reproduction (Ox- ford, England). 2004;19(1):41-7.
• Torres Fernandez ED, Adams KV, Syed M, Maranon RO, Romero DG, Yanes Cardozo LL. Long-Lasting Androgen-Induced Cardiometabolic Ef- fects in Polycystic Ovary Syndrome. Journal of the Endocrine Society. 2018;2(8):949-64.
• Jaatinen TA, Matinlauri I, Anttila L, Koskinen P, Erkkola R, Irjala K. Serum total renin is elevated in women with polycystic ovarian syndrome. Ferti- lity and sterility. 1995;63(5):1000-4.
• Alphan Z, Berberoglu Z, Gorar S, Candan Z, Aktas A, Aral Y, et al. Increa- sed total Renin levels but not Angiotensin-converting enzyme activity in obese patients with polycystic ovary syndrome. Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2013;22(5):475-9.
• Jensterle M, Janez A, Vrtovec B, Meden-Vrtovec H, Pfeifer M, Prezelj J, et al. Decreased androgen levels and improved menstrual pattern after an- giotensin II receptor antagonist telmisartan treatment in four hypertensive patients with polycystic ovary syndrome: case series. Croatian medical journal. 2007;48(6):864-70.
• Hacihanefioglu B, Somunkiran A, Mahmutoglu I, Sercelik A, Toptani S, Kervancioglu E. Effect of hypertension therapy with the angiotensin-con- verting enzyme inhibitor lisinopril on hyperandrogenism in women with polycystic ovary syndrome. Fertility and sterility. 2002;77(3):526-8.
• Mejia-Montilla J, Reyna-Villasmil E, Torres-Cepeda D, Santos-Bolivar J, Reyna-Villasmil N, Bravo-Henriquez A. [Plasma renin and aldosterone le- vels in obese and non-obese women with polycystic ovary syndrome]. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocri- nologia y Nutricion. 2012;59(1):21-7.
• Arefi S, Mottaghi S, Sharifi AM. Studying the correlation of renin-angi- otensin-system (RAS) components and insulin resistance in polycys- tic ovary syndrome (PCOs). Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2013;29(5):470-3.
• Chidambaram M, Duncan JA, Lai VS, Cattran DC, Floras JS, Scholey JW, et al. Variation in the renin angiotensin system throughout the normal menstrual cycle. Journal of the American Society of Nephrology : JASN. 2002;13(2):446-52.
• Bernini G, Bela S, Cionini R, Bardini M, Moretti A, Benelli E, et al., editors. Aldosterone and renin plasma levels in young patients with polycystic ovary syndrome. 8th European Congress of Endocrinology incorporating the British Endocrine Societies; 2006: BioScientifica.